Q-linea AB (publ) (OMX: QLINEA) today announces the company has received 510(k) clearance from the US FDA for its expanded ASTar® Gram-negative Blood Culture menu. The expanded panel represents a sign ...
The expanded panel includes 93 new microorganism-drug combinations, bringing the total panel size to 215, and in conformity with all the most current FDA breakpoints.
A randomized trial involving gram-negative bacterial bloodstream infections found that rapid antibiotic susceptibility ...
Rapid antimicrobial susceptibility testing for gram-negative blood infections shows no improvement in clinical outcomes ...
Among patients with gram-negative bacilli bloodstream infections, rapid blood culture antimicrobial susceptibility testing was not superior to standard testing by desirability of outcome ranking. When ...
This study presents valuable findings by reanalyzing previously published MEG and ECoG datasets to challenge the predictive nature of pre-onset neural encoding effects. The evidence supporting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results